Continuous subcutaneous apomorphine monotherapy in Parkinson’s disease
| Autor: | Ewa Papuć, Olga Trzciniecka, Konrad Rejdak |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: | |
| Zdroj: | Annals of Agricultural and Environmental Medicine, Vol 26, Iss 1, Pp 133-137 (2019) |
| Druh dokumentu: | article |
| ISSN: | 1232-1966 1898-2263 |
| DOI: | 10.26444/aaem/99699 |
| Popis: | Introduction and objective Continuous subcutaneous apomorphine (APO) treatment is one of the 3 therapeutic options for advanced Parkinson’s disease (PD), in addition to deep brain stimulation (DBS) and intrajejunal levodopa. Data from previously performed studies show that few PD patients can achieve APO infusion as monotherapy. The current pilot study presents the authors’ experience in achieving APO monotherapy. Material and methods During the last 2 years, 9 patients with APO were treated in the Department of Neurology of the Medical University of Lublin; each patient was offered a 5-day duration APO treatment as monotherapy. The main indication for the APO therapy was advanced PD with motor fluctuations and the patient’s non-agreement for DBS therapy. Mean age of treated patients – 65.11 years, mean disease duration – 7.67 years, mean Hoehn-Yahr – 2.67, mean L-dopa equivalent before APO treatment – 1751.11 mg, mean daily dose of apomorphine as monotherapy – 106.11 ± 14.09 mg. Results All treated patients managed to achieve APO monotherapy. A statistically significant reduction was found in the duration of the ‘off’ states in the observed PD patients on APO monotherapy (p |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|